Saturday, 31 October 2026European Markets

Northern Drilling Stock Plummets 29% Amid Market Sell-Off

Loading stream...

(VIANEWS) - On Friday, Northern Drilling (NODL.OL) shares fell by 29.15% to close at kr1.67 and extend their four-session losing streak. Meanwhile, the Oslo Bors Benchmark Index_GI dipped 0.12%, continuing its downtrend from yesterday. Furthermore, current trading sessions appear negative, as NORTHERN DRILLING remains significantly below its 52-week high of kr34.90; its last close at kr2.35 represents 93.27% lower than this peak price.

About NORTHERN DRILLING

Northern Drilling Ltd. of Bermuda specializes in ultra-deep water environments and was established in 2017 to acquire and operate offshore drilling assets for use by oil and gas industries.

Yearly Analysis

At its current price of kr1.67 per share and its 52-week high of kr34.90, it is evident that Northern Drilling stock may be trading significantly below its historical high point - suggesting it may be undervalued and offering investors who believe in its long-term prospects an opportunity to purchase it at a cheaper cost. However, investors must also be mindful that the stock is trading well above its 52-week low of KR0.31. While this might indicate the stock's potential for growth, investors should also examine why it reached this low point and whether these issues have been addressed or still exist. Overall, investors should do extensive research on NORTHERN DRILLING's fundamentals and outlook to ascertain whether its stock is an ideal investment at its current price and whether it has potential to reach its 52-week high in the future.

Technical Analysis

Northern Drilling stock has experienced an astounding decline recently, falling below both its 50-day and 200-day moving averages and signalling an adverse market trend. Furthermore, its last reported volume is 15.8% higher than usual which suggests increased investor interest. Looking at NORTHERN DRILLING's volatility, NORTHERN DRILLING experienced a negative 22.40% intraday variation over the last week; positive 0.33% for the last month; and 11.86% in terms of quarterly variation - all exceeding its previous record high amplitude volatility by at least 25%! In terms of average volatility this stock saw highest average amplitude variance over its past quarter: 22.40% per week, 15.65% in month one and 11.86% total variance during quarter three. Based on its stochastic oscillator, Northern Drilling stock is currently considered overbought (>=80), signaling that investors should exercise caution when investing in it now. This should serve as a warning sign and investors should exercise extreme care when considering investing at this time. Overall, Northern Drilling stock is currently experiencing bearish trends with an overbought condition and significant price decline. Investors should carefully consider these aspects before making investment decisions.

Equity Analysis

Northern Drilling's trailing twelve months earnings per share (EPS) stands at kr-6.12. This signifies that they have experienced a loss per share over the past year, signaling to investors that perhaps profits may not be being generated for shareholders. ROE for the 12 trailing months stands at negative -4.22%. ROE measures profitability relative to shareholder equity, so a negative ROE indicates that profits aren't being generated efficiently by the business. Northern Drilling's financial metrics demonstrate that, over the past year, they have not generated sufficient profits. Investors should take this into consideration and do additional research prior to making investment decisions regarding Northern Drilling; alternatively, wait until positive indicators and increased profitability appear before investing.

More news about NORTHERN DRILLING (NODL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com